Anti-Human OX40L (Oxelumab) - PE
| Code | Size | Price |
|---|
| LEI-LT1304-50ug | 50 ug | £265.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Antibody Isotype: Human IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: R4930
Regulatory Status: RUO
Target Species: Human
Applications:
- Flow Cytometry
- Functional Study
Shipping:
2-8°C
Storage:
This R-phycoerythrin (R-PE) conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
R-phycoerythrin (PE)
Format:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Original antibody raised against Human OX40L
Long Description:
Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects.
NCBI Gene:
7292
Target:
TNFSF4
References
1. Mahmood,T. and Yang, P. (2012) N Am J Med Sci. 4(11): 533?536
2. Spicer, P. and Runkel, L. (2019) Expert Opin Investig Drugs. 28(2):99-106
3. Heo, YS. et al. (2014) Bio Design 2(2):55-61